Yano, Hiroki
Onoue, Kenji
Tokinaga, Shiho
Ioka, Tomoko
Ishihara, Satomi
Hashimoto, Yukihiro
Nakada, Yasuki
Nakagawa, Hitoshi
Ueda, Tomoya
Seno, Ayako
Nishida, Taku
Watanabe, Makoto
Saito, Yoshihiko
Funding for this research was provided by:
MEXT KAKENHI (JP22520907)
Article History
Received: 25 November 2022
Accepted: 26 April 2023
First Online: 12 May 2023
Competing interests
: Saito Y. has received research funds from Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Bristol-Myers Squibb Company, Actelion Pharmaceuticals Japan Ltd., Kyowa Kirin Co., Ltd., Kowa Pharmaceutical Co., Ltd, Shionogi & Co., Ltd, Dainippon Sumitomo Pharma Co., Ltd., Teijin Pharma Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nihon Medi-Physics Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc. and Fuji Yakuhin Co., Ltd., research expences from Novartis Pharma K.K., Roche Diagnostics K.K., Amgen Inc., Bayer Yakuhin, Ltd., Astellas Pharma Inc. and Actelion Pharmaceuticals Japan Ltd., speakers’ bureau/honorarium from Alnylam Japan K.K., AstraZeneca K.K., Otsuka Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Tsumura & Co., Teijin Pharma Ltd., Toa Eiyo Ltd., Nippon Shinyaku Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Bayer Yakuhin Ltd., Pfizer Japan Inc., Bristol-Myers Squibb Company and Mochida Pharmaceutical Co., Ltd., consultation fees from Ono Pharmatical Co., Ltd. and Novartis Pharma K.K.; Other authors have no disclosures.